BeyondSpring BYSI
NASDAQ BYSI
$0.72 +0.00 (+0.00%)
At close: Aug 21, 2026 · 4:00 PM EDT

BeyondSpring (BYSI) Liabilities from Discontinued Operations (2023 - 2026)

BeyondSpring (BYSI) posted Liabilities from Discontinued Operations of 9263000.0 for Q1 2026, down 16.8% sequentially from 11133000.0 in Q4 2025, and down 4.83% YoY from 9733000.0 in Q1 2025.

BeyondSpring (BYSI) Liabilities from Discontinued Operations (2023 - 2026) Analysis & Trends

BeyondSpring has reported Liabilities from Discontinued Operations for 4 years, with the latest figure at 9263000.0 in Q1 2026.

  • Quarterly Liabilities from Discontinued Operations fell 4.83% year-over-year to 9263000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9263000.0 (down 4.83% YoY) and the FY2025 annual result came in at 11133000.0, up 26.32% from the prior year.
  • Liabilities from Discontinued Operations declined to 9263000.0 in Q1 2026 per BYSI's latest filing, from 11133000.0 in the prior quarter.
  • Over five years, Liabilities from Discontinued Operations peaked at 11133000.0 in Q4 2025 and troughed at 7847000.0 in Q4 2023.
  • A 4-year average of 9573714.29 and a median of 9619000.0 in 2025 frame the typical range for Liabilities from Discontinued Operations.
  • The sharpest annual moves came in 2025 and 2026: Liabilities from Discontinued Operations increased 26.32% in 2025, then dropped 4.83% in 2026.
  • Over 4 years, Liabilities from Discontinued Operations stood at 7847000.0 in 2023, then grew by 12.31% to 8813000.0 in 2024, then increased by 26.32% to 11133000.0 in 2025, then fell by 16.8% to 9263000.0 in 2026.
  • According to Business Quant data, Liabilities from Discontinued Operations over the past three periods registered 9263000.0, 11133000.0, and 10608000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 BeyondSpring 29.85 Mn 29.85 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2026 10.79 Mn
Jun 30, 2026 10.79 Mn
Mar 31, 2026 9.26 Mn
Mar 31, 2026 9.26 Mn
Dec 31, 2025 11.13 Mn
Dec 31, 2025 11.13 Mn
Sep 30, 2025 10.61 Mn
Sep 30, 2025 10.61 Mn
Jun 30, 2025 9.62 Mn
Jun 30, 2025 9.62 Mn
Mar 31, 2025 9.73 Mn
Mar 31, 2025 9.73 Mn
Dec 31, 2024 8.81 Mn
Dec 31, 2024 8.81 Mn
Dec 31, 2023 7.85 Mn
Dec 31, 2023 7.85 Mn